Scientific interest in Clustered Regularly Interspaced Palindromic Repeats (CRISPR) systems exploded in 2012/2013 when focus shifted from their natural function as a component of adaptive bacterial immunity to their use as a toolkit to find, cut and replace DNA at a specific location in eukaryotes. Widely considered to be a breakthrough technology, the speed of adoption of this technology has been phenomenal. Catherine Coombes, Senior Patent Attorney at HGF Limited concentrates on applications of CRISPR.
The adaption of CRISPR/Cas9 systems as a tool kit to find, cut and replace DNA at a specific location in eukaryotes has resulted in a major breakthrough in gene editing technology, says Catherine Coombes of HGF
The path from the discovery of the CRISPR/Cas mechanism as part of bacteria’s adaptive immune system to the use of this pathway in the food industry and later as a breakthrough gene-editing tool is a good illustration of the power of collaboration among scientists across disciplines.
Last year, a select collection of CRISPR Cas9 enthusiasts gathered to debate both the bright future and the flaring issues facing the technique, which has trail-blazed its way through the market...
The timeline spans from 2011 and the discovery of a second RNA to recent advancements in 2016, outlining the major experiments that took place to lead CRISPR to where it is today.
Check out the agenda and learn how experts in the field are using CRISPR and what advancements they expect in the near future!
Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.
Curious to see who will be joining you at the 1st annual CRISPR Summit USA? Check out our anticipated attendee list to see who will potentially be joining us!